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Abstract 
Background: This study aimed to investigate the predictors of quality of life (QOL) in patients with 
chronic thromboembolic pulmonary hypertension (CTEPH), changes in QOL after surgical and 
medical treatments, and the relationship between baseline QOL and survival. 
Methods and Results: QOL was measured in 128 patients with CTEPH (male/female: 42/86, age: 
56 ± 12 yr, surgical/medical: 65/63) using the Short Form 36 (SF-36). Multiple regression analysis 
showed pulmonary vascular resistance (PVR) and 6-min walking distance (6MWD) were associated 
with physical functioning (PF) (p < 0.01) and physical component summary (PCS) (p < 0.01). Seven 
subscales and two summary scores improved significantly in the surgical group and six subscales and 
mental component summary in the medical group, although the change in QOL was greater in the 
surgical group. The patients in the conventional therapy group with higher PF had significantly better 
survival compared with those with lower PF (5-yr survival: 89.5% vs. 50.8%, p = 0.002). This 
difference in survival was not observed in the group receiving pulmonary arterial hypertension 
(PAH)-specific therapy (100% vs. 100%, p = 0.746). 
Conclusions: PVR and 6MWD were associated with PF or PCS in CTEPH patients. QOL improved 
after surgical or medical therapies, with a greater change in the surgical group. PAH-specific therapy 
improved survival in patients with lower PF at diagnosis. 
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Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary 
hypertension caused by non-resolving thromboembolisms of the pulmonary arteries and pulmonary 
vascular remodeling, associated with the development of right heart failure without effective 
treatment and a mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg.1 The optimal treatment is 
lifelong anticoagulants, and pulmonary endarterectomy (PEA) if the thrombi are surgically 
accessible. Patient symptoms, walking distance, resting hemodynamics, quality of life (QOL), and 
WHO functional class have all been reported to improve after successful PEA.
2-4
 
On the other hand, the prognosis of CTEPH in medically-treated patients is considered to be 
poor, with 3-yr survival as low as 40% in patients with a mPAP >30 mmHg.
5
 Previously, 
management of these patients was supportive. However, the use of pulmonary arterial hypertension 
(PAH)-specific therapy, including endothelin receptor antagonists (ERA) and phosphodiesterase-5 
inhibitors (PDE-5I), has improved therapeutic outcomes in patients with inoperable CTEPH.
6-8
 
Recently, the soluble guanylate cyclase stimulator, riociguat, has been approved for inoperable 
CTEPH or persistent or recurrent pulmonary hypertension after PEA.
9
 Our group has reported 
previously that PAH-specific therapy was a predictor of survival in medically-treated CTEPH 
patients.
10, 11
 
Various treatments have had favorable outcomes in CTEPH patients and therefore it is 
important to evaluate QOL as a therapeutic endpoint. QOL represents a broad spectrum of human 
experiences related to one’s overall well being, including nonmedical factors.12 Changes in 
physiological measures may not always translate into benefits that can be perceived by the patient.
13
 
Some studies on patients with pulmonary hypertension have provided controversial results and have 
questioned whether improvement in QOL is associated with improvements in laboratory data, 
hemodynamics, exercise capacity, and survival.
14
 Therefore, health-related quality of life (HRQOL) 
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is often measured as an additional endpoint.
15
 
Although therapeutic outcomes may be ameliorated, the effect on QOL in patients with 
CTEPH is not fully understood. The aims of this study were: 1) to determine the predictors of QOL 
in patients with CTEPH, 2) to examine how QOL changed following therapeutic intervention, and 3) 
to investigate the relationship between baseline QOL and patient survival. 
 
Methods 
Subjects 
Between April 1999 and November 2011, a total of 155 patients were diagnosed with 
CTEPH at Chiba University Hospital, and of this group, 128 completed a QOL questionnaire at their 
first admission for diagnostic tests. CTEPH was defined as a mPAP ≥ 25 mmHg with a normal 
wedge pressure in patients with dyspnea on exertion for > 6 months.
16
 Lung perfusion scans were 
also required to demonstrate segmental or larger defects concomitant with normal ventilation scans. 
Helical computed tomography (CT) angiography was used to confirm the diagnosis. Chronic 
thromboembolic findings were confirmed on pulmonary angiography. Of the128 patients, 65 
underwent PEA, while 63 patients were treated medically (Figure 1).  
Assessment of central thrombi 
Central arteries were defined as vessels proximal to segmental branches and were divided 
into four portions.
17
 The central disease (CD) score was calculated as the number of abnormal central 
portions, with a maximal score of 4 (Figure 1). The score was determined using helical CT.  
Assessment of QOL 
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We used the Medical Outcome Study Short Form 36 (SF-36) version 1, a generic measure 
used to evaluate QOL.
18
 SF-36 is a self-administered questionnaire comprised of eight subscales, 
physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), 
vitality (VT), social functioning (SF), role emotional (RE), mental health (MH), and two summary 
scores (physical component summary (PCS) and mental component summary (MCS)). The PCS and 
MCS were calculated from the eight subscales. Each score ranges from 0 to 100, with a higher score 
indicating better QOL. The patients were requested to complete the SF-36 within 2 wk of baseline 
right heart catheterization. We also sent follow-up questionnaires to both medically- or 
surgically-treated patients between 1 and 37 months after the date of diagnosis. Follow-up QOL 
scores were obtained from 46 (71%) surgically-treated patients and 34 (54%) medically-treated 
patients (Figure 1). The study was approved by the ethics committee of Chiba University (approval 
number 826), with written informed consent being obtained from all patients before catheterization. 
Surgical treatment 
The selection criteria for PEA were modified slightly by Moser and colleagus.
19
 The 
criteria used in our study were: (1) mPAP of ≥ 30 mmHg, resulting in a calculated PVR of ≥ 300 
dyn.s.cm
-5
, even after oral anticoagulant therapy for > 6 months; (2) WHO functional class of ≥ 2; 
(3) thrombi defined as accessible to current surgical technique (i.e. in main, lobular, or segmental 
arteries); and (4) absence of severe associated disease
20
. A median sternotomy under 
cardiopulmonary bypass with deep hypothermia and circulatory arrest technique was performed in 
65 of the 128 patients in the study. The major reasons for exclusion for surgery at that time were mild 
disease (mPAP < 30 mmHg or PVR < 300 dyn.s.cm
-5
 (3.75 Wood unit [WU]) (n = 10), WHO class II 
with mild symptoms (n = 1), relatively peripheral type (n = 46), severe comorbidities (n = 2), and age 
> 70 yr or unwillingness to undergo surgery (n = 4). 
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Medical treatment 
A total of 63 patients were treated medically in this study. Warfarin was prescribed for all 63 
patients to obtain a target international normalized ratio prothrombin time of 2 ~ 3 and long-term 
oxygen therapy (LTOT) of 92% in the group. In Japan, the oral prostanoid, beraprost, has been 
available as off-label use since 1999. We defined warfarin, LTOT, and oral beraprost as conventional 
therapy. Although bosentan and sildenafil are off-label use for CTEPH, we have used them since 
2005, and define them as PAH-specific therapy in accordance with our previous report.
10
 
Survival analysis in medically-treated patients 
At December 2011, 51 patients in the medically-treated group had survived, while 12 had 
died. Survival time was calculated from the date of diagnosis by right heart catheterization. We 
divided the 63 medically-treated patients into two groups: conventional therapy group (n = 33) and 
PAH-specific therapy group (n = 30). Of the 34 patients with follow-up SF-36 scores available, 23 
had received conventional therapy and 11 PAH-specific therapy (Figure 1).   
The patients were also stratified into two groups using the median PF value at diagnosis of 
55. The resulting 4 groups were defined as follows: group 1, conventional/PF ≥ 55 (n = 19); group 2, 
conventional/PF < 55 (n = 13); group 3, PAH-specific/PF ≥ 55 (n = 13) and group 4, 
PAH-specific/PF < 55 (n = 17). One patient was excluded because the PF value was not available. 
The baseline characteristics of the patients, hemodynamics, and survival were compared between the 
four groups (Table 2).  
Statistical analysis 
The results were expressed as mean ± SD for continuous variables and analyzed using 
Student’s t-test. Multiple regression analysis was used to identify the factors associated with PF and 
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PCS in the CTEPH patients. Survival curves were analyzed by the Kaplan-Meier method using the 
log-rank test to compare survival. P values < 0.05 were considered statistically significant. The 
statistical analyses were performed using JMP version 9.0 (SAS Institute). 
 
Results 
Patient characteristics 
The baseline characteristics of all the patients are summarized in Table 1. The age at 
diagnosis ranged between 18 to 78 yr, with a mean of 56 ± 12 yr. The study population contained 
more female patients (n = 86) than male patients (n = 42). Baseline mPAP, cardiac index (CI), PVR, 
and arterial oxygen tension (PaO2) were 45 ± 12 mmHg, 2.6 ± 0.7 L/min/m
2
, 10.0 ± 4.5 WU, and 58 
± 10 Torr, respectively. The 6MWD was 349 ± 94 m. 
Comparison of SF-36 and clinical variables 
Univariate analysis showed significant correlation between PvO2 (r = 0.49, p < 0.0001; r = 
0.30, p = 0.0009), right atrial pressure (RAP) (r = -0.29, p = 0.0013; r = -0.24, p = 0.0084), CI (r = 
0.41, p < 0.0001; r = 0.24, p= 0.0087), PVR (r = -0.46, p < 0.0001; r = -0.40, p < 0.0001), 6MWD (r 
= 0.54, p < 0.0001; r = 0.46, p < 0.0001), serum BNP (r = -0.41, p < 0.0001; r = -0.30, p = 0.0008) 
and PF or PCS, respectively (Table S1). Multiple regression analysis demonstrated that higher 
6MWD and lower PVR were associated with a higher PF or higher PCS (Table 3). 
Association of SF-36 score and operative mortality 
Of the 65 surgically-treated patients, 6 patients died within 90 days after the operation. 
There was no significant difference in all subscales of the SF-36 between patients who died and 
those who survived. 
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Improvement of QOL by therapeutic intervention 
SF-36 was reassessed at follow-up in 46 of the 65 surgically-treated patients and 34 of the 
63 medically-treated patients. The observation time was 14.0 ± 10.1 and 15.3 ± 9.7 months, 
respectively. In the surgically-treated group, all the SF-36 scores except for BP improved 
significantly (Table 4), whereas in the medically-treated group, PF, RP, VT, SF, RE, MH, and MCS 
improved significantly (Table 5). RP, VT, RE, MH, and MCS improved significantly in the 
conventional therapy group, while PF, VT, SF, RE, and MCS improved significantly in the 
PAH-specific therapy group (Tables S2 and S3). We compared the change in SF-36 scores between 
the surgically- and medically-treated groups and showed ΔPF, ΔRP, ΔGH, and ΔPCS were 
significantly lower in the medically-treated group (Table 6). 
Survival analysis in the medically-treated group 
The 5-yr survival rate from the date of diagnosis in the medically-treated group was 84.7%. 
Ten patients in the conventional therapy group died in the conventional therapy group, compared 
with only two deaths in the PAH-specific therapy group. Figure 2 shows the survival curves of the 
four groups described above with 5-yr survival in group 1 (conventional/PF ≥ 55) of 89.5%, group 2 
(conventional/PF < 55) of 50.8%, group 3 (PAH-specific/PF ≥ 55) of 100%, and group 4 
(PAH-specific/PF < 55) of 100%.  
In the conventional therapy group, group 1 (PF ≥ 55) had better survival than group 2 (PF < 
55). On the other hand, in the PAH-specific therapy group there was no difference in survival 
between group 3 (PF ≥ 55) and group 4 (PF < 55) (p = 0.746). In patients with lower PF (PF < 55), 
the PAH-specific therapy group (group 4) had better survival than the conventional therapy group 
(group 2) (p = 0.019), although 6MWD in group 4 was lower than that measured in group 2 at 
baseline. 
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Discussion 
This study in patients with CTEPH showed a significant association of higher PVR and 
lower 6MWD with lower PF and PCS. Most of the SF-36 subscales improved in both the surgically- 
and medically-treated groups; however, the improvements in PF, RP, GH and PCS in the 
medically-treated group were smaller than those in the surgically-treated group. In the 
medically-treated group, PAH-specific therapy improved survival in patients with a lower PF (PF < 
55) at baseline. This is the largest study to investigate QOL determinants in CTEPH and the 
influence of QOL on survival in medically-treated CTEPH. We found initially that PVR was 
associated with PF and PCS in CTEPH, and that lower PF was associated with poor survival in 
patients treated with conventional therapy, while it was not associated with survival in patients 
receiving PAH-specific therapy. 
There were several issues that needed to be considered when we interpreted our results. PF 
and PCS are the physical components of the SF-36, with our results showing that higher PVR and 
lower 6MWD were associated significantly with the physical components of QOL. In an 
observational study of 22 medically-treated CTEPH patients in Switzerland, the physical subscore of 
the Minnesota Living with Heart Failure Questionnaire (MLHFQ) was associated moderately with 
the New York Heart Association (NYHA) functional class, 6MWD, Borg scale, cardiac index, and 
mixed venous oxygen saturation (r = 0.40 ~ 0.59), whereas hemodynamics, right ventricular systolic 
pressure and mPAP were only weakly correlated (r = 0.20 ~ 0.39).
21
 In a multivariate analysis of 63 
patients with pulmonary hypertension including 15 CTEPH patients, 6MWD, peak oxygen uptake 
and mental disorders were associated with PF of the SF-36.
22
 In addition, in PAH patients, 6MWD 
and the baseline dyspnea index (BDI) correlated strongly with PCS, whereas none of the 
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hemodynamic parameters correlated with PCS.
23
 In contrast to these reports, our results showed that 
PVR correlated with PF and PCS, although the degree of correlation of PVR with PF or PCS was 
only moderate (r = -0.46 and -0.40). Several possible explanations may account for this inconsistency. 
First, we investigated only CTEPH, with PVR being a more important determinant of PF and PCS in 
CTEPH than in PAH. Second, PAH includes more heterogeneous patients, and it is possible that 
QOL in PAH patients with collagen vascular disease may be related to right ventricular function and 
other systemic organ impairment. Third, we investigated a larger number of patients with CTEPH 
than previous reports, and therefore our results could be more reliable. 
Improvement of QOL in the medically-treated group was significant, although this change 
was lower than that observed in the surgically-treated group. However, some of SF-36 subscales 
improved significantly even in the conventional therapy group as well as in the PAH-specific therapy 
group (Tables S2 and S3). In the conventional therapy group, 17 of the 23 patients received oral 
beraprost. Although beraprost has not been approved for CTEPH, Ono et al. reported that it improved 
NYHA functional class in 50% of patients and significantly decreased total pulmonary resistance in 
CTEPH.
24
 It is therefore possible that oral beraprost may have contributed to an improvement in 
QOL in the conventional therapy group. On the other hand, our results did not show an obvious 
advantage of PAH-specific therapy in terms of improvement in QOL compared with the conventional 
therapy group. Possible explanations for this finding are the relatively small samples used to detect 
the difference, and that PDE-5 inhibitors and ERA may not be sufficient to provide better QOL 
compared with beraprost and conventional therapies in patients with CTEPH. 
There are some reports that have shown a correlation between QOL and survival of patients 
with pulmonary hypertension. In a study of 22 CTEPH patients and 26 PAH patients, Cenedese et al. 
reported that patients with a MLHFQ score < 40 had a higher mortality rate compared with patients 
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with a score ≥ 40.21 Fernandes et al. also reported a recent study in 56 patients with PAH that showed 
those with a baseline PCS > 32 in the SF-36 had better survival than those with a PCS < 32.
25
 Our 
results are similar to these reports in that we observed an association between low QOL and poor 
survival. In addition, we demonstrated that PAH-specific therapy improved survival even in patients 
with a lower PF at baseline. On the other hand, in the conventional therapy group, patients with a PF 
≥ 55 had better survival compared with patients with a PF < 55. This indicates that PF could be a 
prognostic factor in patients with CTEPH treated by conventional therapy. 
There were some limitations in our study. First, it was a retrospective, small-sized study, 
especially when evaluating the effectiveness of PAH-specific therapy. Prospective, larger studies are 
therefore needed to clarify the different effects of treatment on QOL in CTEPH. Second, SF-36 
scores are not disease-specific QOL measures and may be less sensitive to changes in QOL in 
CTEPH. In general, generic measures, including SF-36, represent health status that is comparable 
even with the healthy population. In contrast, disease-specific measures are more sensitive to 
treatment. It may therefore be reasonable to use disease-specific measures when evaluating the 
effects of treatment in terms of sensitivity. 
In conclusion, we demonstrated that PVR and 6MWD were associated with PF and PCS in 
patients with CTEPH. QOL improved after surgical or medical therapies, with a greater change in 
QOL being observed in the surgical group. In the medically-treated group, PAH-specific therapy 
improved survival in patients with a low PF at diagnosis. 
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Figures and Tables 
Figure 1. Algorithm of management and course for chronic thromboembolic pulmonary hypertension 
(CTEPH) 
 
CD score, central disease score; QOL, quality of life; PAH, pulmonary arterial hypertension; PF, 
physical function (a SF-36 subscale); PAH, pulmonary arterial hypertension 
The CD score of one patient was not available in the surgically-treated group. Conventional therapy 
includes warfarin, long-term oxygen therapy and oral beraprost. PAH-specific therapy includes 
bosentan and sildenafil. The median value for PF was 55. In the survival analysis, one patient was 
excluded because the PF value was not available. 
  
Survival analysis
128 CTEPH patients
Medically-treated group
n=63
QOL reassessment 
after surgical therapy
n=46
QOL reassessment 
after medical therapy
n=34
CD score
0: n=6
1: n=17
2: n=22
3: n=14
4: n=5
CD score
0: n=35
1: n=19
2: n=7
3: n=2
Dead within 
90 days after 
operation
n=6
PAH-specific therapy n=11
(bosentan n=6, sildenafil n=4,
bosentan+sildenafil n=1)
Conventional therapy n=23
(with oral beraprost n=17)
Surgically-treated group
n=65
Group 1; conventional/PF≥55 (n=19)
Group 2; conventional/PF<55 (n=13)
Group 3; PAH-specific/PF≥55  (n=13)
Group 4; PAH-specific/PF<55 (n=17)
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Table 1. Baseline patient characteristics 
 
Data are expressed as mean ± SD or number. mPAP, mean pulmonary arterial pressure; RAP, right 
atrial pressure; CI, cardiac index; PVR, pulmonary vascular resistance; 6MWD, 6 min walking 
distance; PaO2, arterial oxygen tension; PvO2, mixed venous oxygen tension; BNP, brain natriuretic 
peptide; WHO, World Health Organization. 
  
Parameters
Age (yr) 56 ± 12 55 ± 11 57 ± 14
Sex (male/female) 42 / 86 29 / 36 13 / 50
mPAP (mmHg) 45 ± 12 47 ± 11 43 ± 12
RAP (mmHg) 6 ± 4 7 ± 5 5 ± 4
CI (L/min/m2) 2.6 ± 0.7 2.6 ± 0.7 2.7 ± 0.6
PVR (Wood unit) 10.0 ± 4.5 10.9 ± 4.3 9.1 ± 4.5
6MWD (m) 349 ± 94 347 ± 89 351 ± 98
PaO2 (torr) 58 ± 10 58 ± 9 58 ± 11
PvO2 (torr) 32 ± 4 32 ± 4 33 ± 4
Serum BNP (pg/ml) 232 ± 307 239 ± 259 225 ± 351
WHO class
  Ⅰ 2 0 2
  Ⅱ 34 12 22
  Ⅲ 88 49 39
  Ⅳ 4 4 0
All patients (n=128)
Surgically-treated group
(n=65)
Medically-treated group
(n=63)
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Table 2. Comparison of patient characteristics of the medically-treated grouped according to 
therapeutic agent (conventional or PAH-specific) and PF value. 
 
Data are expressed as mean ± SD or number. Abbreviations as in Figure 1 and Table 1. Group 1, 
conventional/PF ≥ 55 (n=19); Group 2, conventional/PF < 55 (n=13); Group 3, PAH-specific/PF ≥ 
55 (n=13) and Group 4, PAH-specific/PF < 55 (n=17). One patient was excluded because of no PF 
value. 
  
Age (yr) 58.1 ± 11.2 60.8 ± 13.3 50.7 ± 15.0 57.9 ± 13.2
Sex (male/female) 4 / 15 3 / 10 1 / 12 4 / 13
mPAP (mmHg) 36.8 ± 12.6 43.2 ± 12.0 45.8 ± 12.7 46.6 ± 9.6
CI (L/min/m2) 2.99 ± 0.57 2.48 ± 0.55 * 2.60 ± 0.46 * 2.46 ± 0.56
PVR (Wood unit) 6.54 ± 2.44 10.49 ± 6.09 * 9.81 ± 4.26 $ 10.77 ± 3.72
6MWD (m) 398.7 ± 47.9 311.1 ± 120.9 $ 375.3 ± 72.0 292.6 ± 109.6 †
PaO2 (torr) 60.7 ± 11.5 52.2 ± 8.9 †† 61.0 ± 13.6 56.4 ± 9.2
*: p <0.05 compared with group 1
$: p <0.01 compared with group 1
†: p <0.05 compared with group 3
††: p <0.05 compared with group 1 and 3
Group 1 (n=19) Group 2 (n=13) Group 3 (n=13) Group 4 (n=17)
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Table 3. Multiple regression analysis of factors associated with QOL in CTEPH patients 
 
PF, Physical functioning; PCS, Physical component summary; 6MWD, 6 min walking distance; PVR, 
pulmonary vascular resistance 
 
Table 4. QOL at diagnosis and after surgical therapy in the surgically-treated group 
 
Data expressed as the mean ± SD. PF, physical functioning; RP, role physical; BP, bodily pain; GH, 
general health; VT, vitality, SF, social functioning; RE, role emotional; MH, mental health; PCS, 
physical component summary; MCS, mental component summary 
  
β p  value β p  value
6MWD (m) 0.10 <0.0001 0.03 0.0012
PVR (Wood unit) -1.32 0.0072 -0.58 0.0041
R2 0.34 0.27
Adjusted R2 0.33 0.26
PF (n=126) PCS (n=121)
Variables
SF-36 n
PF 46 44.7 ± 24.2 69.9 ± 22.1 $
RP 46 20.7 ± 32.2 62.3 ± 43.7 $
BP 46 71.5 ± 27.9 72.1 ± 25.7
GH 45 35.2 ± 19.4 55.6 ± 18.2 $
VT 44 45.9 ± 22.6 63.4 ± 21.7 $
SF 46 47.6 ± 29.7 64.2 ± 31.5 $
RE 46 42.7 ± 46.4 62.3 ± 45.3 *
MH 45 56.7 ± 20.2 67.1 ± 20.5 $
PCS 44 37.0 ± 8.0 45.1 ± 7.5 $
MCS 44 46.0 ± 8.5 49.4 ± 8.5 *
*: p <0.05
$: p <0.01
At diagnosis After surgical therapy
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Table 5. QOL at diagnosis and after medical therapy in the medically-treated group 
 
Data expressed as the mean ± SD. Abbreviations as in Table 4. 
  
SF-36 n
PF 33 51.1 ± 22.2 60.9 ± 20.5 $
RP 33 26.5 ± 35.3 45.7 ± 40.1 *
BP 33 70.1 ± 24.9 72.2 ± 27.4
GH 33 45.2 ± 18.6 46.5 ± 15.3
VT 31 44.7 ± 23.8 61.5 ± 18.2 $
SF 34 48.5 ± 24.4 62.9 ± 24.7 $
RE 33 45.5 ± 46.3 73.7 ± 42.3 $
MH 31 58.5 ± 25.4 73.2 ± 17.6 $
PCS 30 38.6 ± 9.1 38.1 ± 10.2
MCS 30 45.5 ± 10.4 51.2 ± 8.5 $
*: p <0.05
$: p <0.01
At diagnosis After medical therapy
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Table 6. Comparison of the change in QOL following therapeutic intervention between the 
surgically- and medically-treated group 
 
‘Δ’ refers to the finite differences between SF-36 scores at diagnosis and at follow-up. The extent of 
improvement of physical function (PF), role physical (RP), general health (GH) and, physical 
component summary (PCS) in the surgically-treated group was significantly greater than that in the 
medically-treated group. Abbreviations as in Table 4. 
  
SF-36
ΔPF 25.2 ± 23.4 (46) 9.7 ± 19.3 (33) $
ΔRP 41.7 ± 47.0 (46) 19.2 ± 44.3 (33) *
ΔBP 0.7 ± 32.0 (46) 2.1 ± 32.5 (33)
ΔGH 20.4 ± 23.5 (45) 1.3 ± 16.3 (33) $
ΔVT 17.5 ± 21.3 (44) 16.8 ± 22.2 (31)
ΔSF 16.6 ± 31.3 (46) 14.3 ± 25.2 (34)
ΔRE 19.6 ± 52.9 (46) 28.3 ± 45.7 (33)
ΔMH 10.4 ± 22.5 (45) 14.7 ± 20.0 (31)
ΔPCS 8.0 ± 10.0 (44) -0.6 ± 7.8 (30) $
ΔMCS 3.4 ± 8.5 (44) 5.7 ± 7.3 (30)
*: p <0.05
$: p <0.01
Medical group (n)Surgical group (n)
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Figure 2. Survival curves of patients with medically-treated chronic thromboembolic pulmonary 
hypertension 
 
Patients were classified into four groups according to the therapeutic agent (conventional therapy or 
PAH-specific therapy) and PF value. The median value for PF was 55. Patients with PF < 55 had 
poorer survival than those with PF ≥ 55 under conventional therapy (group 1 vs. 2, p = 0.002). In 
contrast, patients treated with PAH-specific therapy had no difference in survival regardless of PF at 
diagnosis (group 3 vs. 4, p = 0.746). 
Group 1, conventional/PF ≥ 55; Group 2, conventional/PF < 55; Group 3, PAH-specific/PF ≥ 55; 
Group 4, PAH-specific/PF < 55. 
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Table S1. Correlation between SF-36 and the clinical parameters of the patients 
 
mPAP, mean pulmonary arterial pressure; RAP, right atrial pressure; CI, cardiac index; PVR, 
pulmonary vascular resistance; 6MWD, 6 min walking distance; PaO2, arterial oxygen tension; PvO2, 
mixed venous oxygen tension; BNP, brain natriuretic peptide; WHO, World Health Organization; 
PCS, physical component summary; MCS, mental component summary 
  
(n)
Age 0.03 -0.10 -0.02 0.07 0.06 0.05 -0.21 $ 0.00 0.05 0.13
mPAP -0.23 $ 0.03 0.25 $ -0.18 * 0.08 0.03 0.00 0.22 * -0.24 * 0.17
RAP -0.29 $ 0.02 0.15 -0.24 $ -0.01 0.09 0.06 0.06 -0.24 $ 0.05
CI 0.41 $ 0.15 0.04 0.29 $ 0.25 $ 0.12 0.04 0.14 0.24 $ 0.13
PVR -0.46 $ -0.10 0.11 -0.29 $ -0.05 -0.07 0.00 0.08 -0.40 $ 0.08
6MWD 0.54 $ 0.33 $ 0.14 0.08 0.16 0.16 0.17 0.09 0.46 $ -0.10
PaO2 0.14 0.24 $ 0.02 0.16 0.05 0.14 0.29 $ 0.06 0.04 -0.01
PvO2 0.49 $ 0.27 $ 0.06 0.31 $ 0.22 * 0.18 * 0.22 * 0.11 0.30 $ 0.04
Serum BNP -0.41 $ -0.11 0.09 -0.13 -0.10 0.03 -0.09 0.04 -0.30 $ 0.08
WHO class -0.44 $ -0.14 -0.02 -0.32 $ -0.24 $ -0.12 -0.11 -0.15 -0.26 $ -0.12
*: p <0.05
$: p <0.01
(128) (125) (121) (121)(126) (128) (127) (124) (124) (128)
(Physical
functioning)
PF
(Role
physical)
RP
(Bodily
pain)
BP
(General
health)
GH
(Vitality)
VT
(Social
functioning)
SF
(Role-
emotional)
RE
(Mental
health)
MH
PCS MCS
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Table S2, 3. QOL at diagnosis and after conventional therapy (Table S2) and PAH-specific therapy 
(Table S3) in medically-treated group 
Table S2 
 
Tables S3 
 
Data given as mean ± SD. Abbreviations as in Table 4. 
  
SF-36 n
PF 22 55.9 ± 21.7 62.4 ± 20.4
RP 22 29.5 ± 35.9 50.0 ± 40.8 *
BP 22 66.2 ± 26.2 71.3 ± 29.0
GH 23 46.6 ± 17.3 44.9 ± 15.5
VT 21 45.2 ± 21.9 60.8 ± 18.9 $
SF 23 49.5 ± 27.3 59.8 ± 25.0
RE 22 51.6 ± 45.7 77.3 ± 40.4 *
MH 21 58.5 ± 22.0 74.3 ± 15.0 $
PCS 20 39.6 ± 9.6 39.5 ± 9.3
MCS 20 44.5 ± 9.4 49.8 ± 7.2 $
*: p <0.05
$: p <0.01
At diagnosis After conventional therapy
SF-36 n
PF 11 41.6 ± 21.0 57.8 ± 21.2 *
RP 11 20.5 ± 35.0 37.1 ± 39.2
BP 11 77.9 ± 20.8 73.9 ± 25.2
GH 10 41.9 ± 21.9 50.0 ± 14.9
VT 10 43.5 ± 28.5 63.0 ± 17.5 *
SF 11 46.6 ± 17.8 69.3 ± 24.0 $
RE 11 33.3 ± 47.1 66.7 ± 47.1 *
MH 10 58.4 ± 32.7 70.8 ± 22.8
PCS 10 36.7 ± 8.1 35.2 ± 11.9
MCS 10 47.4 ± 12.5 54.0 ± 10.4 $
*: p <0.05
$: p <0.01
At diagnosis After PAH-specific therapy
22 
 
 
 
 
 
 
 
 
 
 
 
 
Urushibara Takashi, et al. Effects of surgical and medical treatment on quality of life 
for patients with thromboembolic pulmonary hypertension. Circulation Journal vol.79 
No.12 2696-2702  
DOI: http://doi.org/10.1253/circj.CJ-15-0538 
Circulation Journal vol.79 No.12 2696-2702 Supplementary materials 
平成 27年 11月 25日公表済 
